1. ALLA AKTIER
  2. NYHETER
  3. COMBIGENE

Combigene

Nyheter Combigene Nyheter alla bolag

Interim report January – September 2023 for CombiGene AB (publ)

MARKN.

July – September 2023
• Net sales: TSEK 992 (5,213).
• Other operating revenues: TSEK 173 (8,285).
• Profit from financial items: TSEK -8,403 (3,953).
• Earnings per share: SEK -0.42 (0.20).

January – September 2023
• Net sales: TSEK 4,948 (21,354).
• Other operating revenues: TSEK 588 (20,888).
• Profit from financial items: TSEK -29,305 (5,785).
• Earnings per share: SEK -1.48 (0.29).
• Cash and cash equivalents: TSEK 107,187 (144,940).

Events during the period
• The Epilepsy Project progresses through optimization activities in preparation for in-human studies. (September 5)
• CombiGene chooses CDMO partner for the COZY01 pain project. (September 15)

Events after the end of the period
• Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene. (October 14)
• CombiGene and Zyneyro choose initial indication in the COZY01 pain project (October 26)
• CombiGene chooses Charles River as preclinical toxicology partner for the COZY01 pain project. (October 31)

Contacts

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Please read Ingeneious, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com

Attachments

CombiGene Q3 2023 EN

Datum 2023-11-10, kl 09:00
Källa MFN
Bifogade filer
CombiGene Q3 2023 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!